Compassionate use of remdesivir in children with COVID-19 https://doi.org/10.1007/s00431-020-03876-1 A nationwide multicenter observational study was conducted on children with confirmed SARS-CoV-2 receiving compassionate treatment with RDV in Spain. Eight patients were included in the study, four infants and four older… Continue reading "(18 Nov 2020) Remdesivir- study on children showed successful outcomes"
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial https://doi.org/10.1016/S2213-2600(20)30511-7 This trial is registered with Clinicaltrialsregister.eu (2020-001023-14) and ClinicalTrials.gov (NCT04385095); the pilot trial of inpatients with COVID-19 is… Continue reading "(16 Nov 2020) Interferon beta- nebulised interferon beta 1a helped in rapid recovery"
Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis https://doi.org/10.1007/s10875-020-00911-6 Among the 96 patients included (81% male, mean (SD) age: 60 (12.5) years), underlying conditions, baseline disease severity, and concomitant medications were broadly similar between the tocilizumab (n =… Continue reading "(15 Nov 2020) Tocilizumab- associated with a reduced need for overall ventilatory support"
Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia https://www.ijidonline.com/article/S1201-9712(20)32319-5/pdf A total of 89 patients underwent randomization with 49% (n = 44) assigned to favipiravir… Continue reading "(13 Nov 2020) Favipiravir, Interferon beta- no significant differences in clinical outcome in comparison to HCQ"
Treatment with Tocilizumab for Patients with Covid-19 Infections: A Case-series Study https://doi.org/10.1002/jcph.1787 This retrospective, observational study included 38 patients with an average age of 63 years (IQR: 48-70). The average dose of TCZ given was 519 +/- 61 mg. The… Continue reading "(13 Nov 2020) Tocilizumab- beneficial in COVID-19 cytokine storm"
Corticosteroids are associated with increased survival in elderly presenting severe SARS-Cov2 infection https://www.medrxiv.org/content/10.1101/2020.11.10.20226886v1 Among the 267 patients included in the analysis, 96 were assigned to the treatment group. Median age was 86, interquartile range 83 to 90 and 95% had… Continue reading "(13 Nov 2020) Corticosteroids- associated with increased survival in elderly"
Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19 https://doi.org/10.1016/j.ejim.2020.10.020 The aim of this study was to evaluate the effects of subcutaneous tocilizumab, a recombinant humanized monoclonal antibody against the interleukin-6 receptor on coagulation parameters. Hospitalized… Continue reading "(10 Nov 2020) Tocilizumab-associated with significant improvement of blood coagulation parameters"
A shorter symptom-onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis https://www.medrxiv.org/content/10.1101/2020.11.05.20226373v1.full.pdf Of 350 patients treated with remdesivir, 346 were included for the final analysis (males: 270 [78.0%]; median [range] age:… Continue reading "(10 Nov 2020) Remdesivir- associated with a significant mortality benefit"
Impact of tocilizumab administration on mortality in severe COVID-19 https://doi.org/10.1038/s41598-020-76187-y A single-center propensity-score matched cohort study, including all consecutive COVID-19 patients, admitted to the medical center who were either discharged from the medical center or expired between March 1, 2020,… Continue reading "(07 Nov 2020) Tocilizumab- not found useful for management of cytokine storm"
Safety and efficacy of Artemisinin-Piperaquine for treatment of COVID-19: an open-label, non-randomized, and controlled trial https://doi.org/10.1016/j.ijantimicag.2020.106216 In an open label clinical trial (ChiCTR2000033049), Forty-one patients with confirmed COVID-19 were enrolled in the study and divided into two groups: artemisinin-piperaquine (AP)… Continue reading "(06 Nov 2020) Artemisinin- in combination with Piperaquine significantly reduced the time to reach undetectable SARS-CoV-2"
